Common Femoral Artery StenosisShockifyNCT06829914
Shockwave™ vs Surgical Endarterectomy for Calcified Severe Common Femoral Artery Stenosis: Comparison of Efficacy, Safety and Long-Term Outcomes
A study testing Shockwave Catheter and CFA Endarterectomy in people with Common Femoral Artery Stenosis and Calcification; Heart, run by Baylor Research Institute at 1 site in United States.
Trial summary
The investigators hypothesize that Shockwave with DCB is non-inferior to surgical endarterectomy for common femoral artery (CFA) stenosis with regard to primary efficacy and safety endpoints. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Common Femoral Artery Stenosis, Calcification; Heart
- What is being tested?
- Shockwave Catheter and CFA Endarterectomy
- Type of treatment
- Injection or infusion, Medical device, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteUnited States
- Study dates
- 7 Mar 2024to 30 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- A patient will be eligible for inclusion in this study if he or she meets all of the following criteria (confirmed by core lab):
- CFA atherosclerotic stenosis 60-100%
- Moderate to severe calcification reported on imaging
- Lifestyle-limiting intermittent claudication (IC) or chronic limb-threatening ischemia (CLTI) as described by Rutherford chronic limb ischemia (CLI) category 2-5
- Failing conservative therapy
- Operative candidate for CFE prior to enrollment
- ≥18 years of age
Who cannot join
- A patient will be ineligible for inclusion in this study if he or she meets any of the following criteria:
- History of CFE or bypass in affected limb
- Thrombosis of affected CFA
- Aneurysm in the common femoral artery of target limb
- Known target lesion restenosis (re-narrowing of the artery to ≥50% following the alleviation of a previous narrowing within 3 months)
- Any preceding percutaneous cardiovascular intervention within 2 weeks
Show all 14Show fewer
- Inability to tolerate DAPT
- Known coagulopathy or bleeding diathesis, thrombocytopenia with platelet count <100,000/µL
- Uncontrolled diabetes (HbA1c ≥10.0%)
- Non-ambulatory
- Extensive tissue loss requiring amputation or salvageable only with complex foot reconstruction or non-traditional transmetatarsal amputations
- MI within 6 weeks (defined as presumed ischemic symptoms (chest pain, ST-segment deviation and troponin higher than 2 times the upper limit of normal))
- Stroke within 3 months (defined as sudden transient or irreversible focal neurological deficit resulting from a cerebrovascular cause)
- Pregnant
Trial locations and contacts
1 site in 1 country.
United States1 site
Baylor Scott & White The Heart Hospital - Plano
Plano, Texas, 75093
About this study
The investigators hypothesize that Shockwave with DCB is non-inferior to surgical endarterectomy for common femoral artery (CFA) stenosis with regard to primary efficacy and safety endpoints. The study will challenge the current guideline that recommends common femoral endarterectomy (CFE) as the primary treatment for symptomatic CFA stenosis.
Read the detailed description
This is a pilot, prospective, randomized clinical trial. This trial compares patients with severe symptomatic moderate to severe calcified CFA stenosis undergoing traditional gold standard CFA endarterectomy to innovative technique of endovascular treatment using Shockwave™ Intra vascular Lithotripsy (IVL) using M5+ balloon with Drug coated balloon to achieve removal and debulking of plaque and achieve luminal gain. Patients who meet inclusion criteria will be informed and consented by a clinical coordinator if they wish to participate in the trial. If participants are candidates for surgery, they will then be randomized into one of two cohorts, receiving either Shockwave™ IVL + DCB (drug-coated balloon) procedure or a standard surgical endarterectomy. The study compares the 1-year efficacy and 6-month safety outcomes post-procedure for patients with severe, symptomatic CFA stenosis receiving Shockwave™ IVL with DCB versus surgical endarterectomy.
- Being tested
- Shockwave Catheter, CFA Endarterectomy
- Medical subject headings
- Calcinosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Shockwave CatheterDevice
Shockwave™ IVL + DCB procedure
CFA EndarterectomyProcedure or surgery
Standard CFA endarterectomy
| Study group | Role | What they receive |
|---|---|---|
| Shockwave Catheter | Active comparator | Shockwave™ Intravenous Lithotripsy (IVL)+ DCB (Drug Coated Balloon) Receives: Device: Shockwave Catheter |
| surgical endarterectomy | Active comparator | Surgery should be performed with patch angioplasty, with or without profunda femoris endarterectomy. Receives: Procedure: CFA Endarterectomy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Clinically driven target lesion revascularization (cdTLR (symptom-driven repeat revascularization of the index lesion))
Measured: Procedure date through 1-year post-op
Restenosis to ≥ 50% of the target lesion on angiography or follow-up ultrasound
Measured: Procedure date through 1-year post-op
Freedom from perioperative death
Measured: Procedure date through 30 days post-op
Freedom from major adverse cardiovascular events (MACE (stroke, myocardial infarction (MI), cardiovascular death))
Measured: Procedure date through 30 days post-op
Freedom from major adverse events
- Acute occlusion of the target lesion
- Flow-limiting dissection of the target lesion
- Symptomatic thrombus or embolus in treated limb requiring treatment
- Unplanned percutaneous/surgical revascularization or amputation above the ankle of the treated limb
- Access/surgical site complications
- Bleeding events (specify Bleeding Academic Research Consortium (BARC) type - see Appendix 18.2)
- Surgical site infection requiring medication or surgery, wound dehiscence, patch/arterial infection, lymphatic leak requiring surgery
Measured: Procedure date through 6 months post-op
Secondary outcomes (22)
Mortality
Measured: Procedure date through 1-year post-op
Rutherford Chronic Limb Ischemia (CLI) Category
https://www.ncbi.nlm.nih.gov/books/NBK553864/table/ch20.Tab2/#
Stage 0 - Asymptomatic. Stage 1 - Mild claudication - Completes treadmill exercise; Ankle Pressure (AP) after exercise >50 mmHg but at least 20 mmHg lower than resting value.
Stage 2 - Moderate claudication - Between categories 1 and 3. Stage 3 - Severe claudication - Cannot complete standard treadmill exercise and AP after exercise <50 mm Hg.
Stage 4 - Ischemic rest pain - Resting AP <40 mm Hg, flat or barely pulsatile ankle or metatarsal pulse volume recording (PVR); Toe Pressure (TP) < 30 mm Hg.
Stage 5 - Minor tissue loss-nonhealing ulcer, focal gangrene with diffuse pedal ischemia- Resting AP < 60 mm Hg, ankle or metatarsal PVR flat or barely pulsatile; TP < 40 mm Hg Stage 6 - Major tissue loss-extending above TM level, functional foot no longer salvageable - Same as category 5
Measured: 30 days post-op, 3 months post-op, 6 months post-op, 1 year post-op
Treatment satisfaction and quality of life (PAQ)
Measured by the Peripheral Artery Questionnaire (PAQ), a 20-question questionnaire measuring peripheral vascular disease affect on quality of life. Questionnaires may be completed in-person or via phone call conducted by the study coordinator.
Measured: Pre-op, 30 days post-op, 6 months post-op, 1 year post-op
Intraoperative blood transfusion > 4 minutes
Measured: Intra-op
Procedural duration (minutes)
Measured: Intra-op
Length of stay (days)
Measured: Procedure date through 1 year post-op
Postoperative anemia requiring blood transfusion
Measured: Procedure date through 30 days post-op
Readmissions
Measured: 30 days post-op, 30 days post-discharge
Return to the operating room / angiography suite
Measured: 30 days post-op
Access/surgical site complications
- Superficial wound infection
- Deep wound infection
- Wound dehiscence
- Pseudoaneurysm identified on physical exam, imaging or angiography
- Hematoma identified on physical exam, imaging or angiography
Measured: 30 days post-op, 6 months post-op
Pneumonia (number of cases)
Patients must meet criteria from both sections:
Radiology: One definitive chest radiological exam (x-ray or CT) with at least one of the following:
- New or progressive and persistent infiltrate
- Consolidation or opacity
Patients with underlying pulmonary or cardiac disease require two serial chest radiological exams (x-ray or CT) taken no less than 12 hours apart, but no more than 7 days apart.
Signs/Symptoms/Laboratory: at least one of the following:
- Fever (>38 C) with no other recognized cause
- Leukopenia (<4000 WBC/mm3) or leukocytosis (≥12,000 WBC/mm3)
- For adults ≥ 70 years old, altered mental status with no other recognized cause and at least one of the following:
- 5% Bronchoalveolar lavage (BAL)
- Positive growth in blood culture not related to another source of infection
- Positive growth in culture of pleural fluid
- Positive quantitative culture from minimally contaminated lower respiratory tract (LRT) specimen
Measured: Procedure date through 30 days post-op
Prolonged intubation
Intubation greater than 48 hours postoperatively
Measured: Procedure date through 30 days post-op
Urinary tract infection
Must meet one of the following TWO criteria within 30 days of the operation:
- fever (>38C)
- urgency
- frequency
- dysuria
- suprapubic tenderness
AND urine culture of >105 colonies/mL urine with no more than two species of organisms
OR two of the following:
- fever (>38C)
- urgency
- frequency
- dysuria
- suprapubic tenderness
AND any of the following:
- dipstick test positive for leukocyte esterase and/or nitrite
- pyuria (>10WBCs/mL or >3 WBC/hpf of unspun urine)
- organisms seen on Gram stain of unspun urine
- two urine cultures with repeated isolation of the same uropathogen with >102 colonies/mL urine in non-voided specimen
- urine culture with <105 colonies/mL urine of single uropathogen in patient being treated with appropriate antimicrobial therapy
- physician's diagnosis
- physician institutes appropriate antimicrobial therapy
Measured: Procedure date through 30 days post-op
Sepsis
The disorder spectrum spans from relatively mild physiologic abnormalities to septic shock. The most significant level is reported using the following criteria: SIRS (Systemic Inflammatory Response Syndrome), clinically recognized by the presence of two or more of the following in the same time frame:
Temp >38 degrees C or 90 bpm RR >20 breaths/min or PaCO2 12,000 cell/mm3, 10% immature (band) forms anion gap acidosis. Report if the patient has clinical signs and symptoms of SIRS listed above and meets either A or B:
- One of the following:
- Positive blood culture
- Clinical documentation of purulence or positive culture
- Suspected pre-operative infection or bowel infarction leading to the surgical procedure. Procedural findings must confirm this suspected diagnosis with one or more of the following:
- Confirmed infarcted bowel requiring resection
- Purulence in the operative site
- Enteric contents in the operative site
- Positive intra-operative cultures
Measured: Procedure date through 30 days post-op
Septic shock
Report this variable if the patient has sepsis AND documented organ and/or circulatory dysfunction. Examples of organ dysfunction include: oliguria, acute alteration in mental status, acute respiratory distress. Examples of circulatory dysfunction include: hypotension, requirement of inotropic or vasopressor agents. The presence of pneumatosis along with the presence of SIRS is assigned.
Measured: Procedure date through 30 days post-op
Graft failure
Mechanical failure of an extracardiac graft or prosthesis including myocutaneous flaps and skin grafts requiring return to the operating room, interventional radiology or a balloon angioplasty within 30 days of the operation.
Measured: Procedure date through 30 days post-op
Cardiac arrest
The absence of cardiac rhythm or presence of chaotic cardiac rhythm, intraoperatively or postoperatively, which results in a cardiac arrest requiring the initiation of CPR, which includes chest compressions. Patients are included who are in a pulseless VT or Vfib in in which defibrillation is performed and PEA arrests requiring chest compressions. Patients with automated implantable cardioverter defibrillator (AICD) that fire but the patient has no loss of consciousness should be excluded.
Measured: Procedure date through 30 days post-op
Myocardial infarction
Documentation of one or more of the following changes indicative of acute MI:
- ST elevation >1mm in two or more contiguous leads
- New left bundle branch block
- New q-wave in two or more contiguous leads
- New elevation in troponin greater than 3 times the upper level o f the reference range in the setting of suspected myocardial ischemia
Measured: Procedure date through 30 days post-op
Acute kidney injury
In a patient who did not require dialysis preoperatively, worsening of renal dysfunction postoperatively requiring hemodialysis, peritoneal dialysis, hemofiltration, hemodiafiltration, or ultrafiltration
Measured: Procedure date through 30 days post-op
Dialysis
Initiation of hemodialysis, peritoneal dialysis, hemofiltration, hemodiafiltration or ultrafiltration in a patient not previously on said therapy preoperatively
Measured: Procedure date through 30 days post-op
Deep vein thrombosis
New diagnosis of blood clot or thrombus within the venous system (superficial or deep) which may be coupled with inflammation and requires treatment. Must be noted within 30 days after the principal operative procedure AND one of the following A or B below:
A.New Diagnosis of a [new] venous thrombosis (superficial or deep), confirmed by a duplex, venogram, CT scan, or any other definitive imaging modality (including direct pathology examination such as autopsy) AND the patient must be treated with anticoagulation therapy and/or placement of a vena cava filter or clipping of the vena cava, or the record indicates that treatment was warranted but there was no additional appropriate treatment option available.
- As per (A) above, but the patient or decisionmaker has refused treatment. There must be documentation in the medical record of the [patient's] refusal of treatment.
Measured: Procedure date through 30 days post-op
Pulmonary embolism
Lodging of a blood clot in the pulmonary artery with subsequent obstruction of blood supply to the lung parenchyma. The blood clots usually originate from the deep leg veins or pelvic venous system. Since there are not always preoperative studies proving that a clot or thrombus was not present preoperatively, the technical specification of the variable requires only a "new diagnosis"- in other words the clot or thrombus was not previously known. A pulmonary embolism must be noted within 30 days after the principal operative procedure AND the following criteria, A AND B below:
- New diagnosis of a new blood clot in a pulmonary artery
AND
- The patient has a V-Q scan interpreted as high probability of pulmonary embolism or a positive CT exam, TEE, pulmonary arteriogram, CT angiogram, or any other definitive imaging modality (including direct pathology examination such as autopsy
Measured: Procedure date through 30 days post-op
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Feb 2025
- Study start7 Mar 2024
- Primary completion3 Nov 2026
- Study completion30 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (17)Papers the sponsor has linked to this study.
- Other trials for Common Femoral Artery StenosisStudies of the same condition, open and under way.
- More trials run by Baylor Research InstituteThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Prospective, randomized pilot study
- Masking
- None (open label)
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Baylor Research Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Sameh Sayfo, MD, Principal investigator, Baylor Scott & White The Heart Hospital - PlanoJohn Kedora, MD, Principal investigator, Baylor Scott & White The Heart Hospital - Plano
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06829914
- Sponsor's protocol ID
- 021-263
- Acronym
- Shockify
- Status last verified
- Jun 2026
- First submitted
- 1 Oct 2024
- Last updated
- 6 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Publications
Kang JL, Patel VI, Conrad MF, Lamuraglia GM, Chung TK, Cambria RP. Common femoral artery occlusive disease: contemporary results following surgical endarterectomy. J Vasc Surg. 2008 Oct;48(4):872-7. doi: 10.1016/j.jvs.2008.05.025. Epub 2008 Jul 17.
PubMed 18639427Kuma S, Tanaka K, Ohmine T, Morisaki K, Kodama A, Guntani A, Ishida M, Okazaki J, Mii S. Clinical Outcome of Surgical Endarterectomy for Common Femoral Artery Occlusive Disease. Circ J. 2016;80(4):964-9. doi: 10.1253/circj.CJ-15-1177. Epub 2016 Feb 19.
PubMed 26902450Nguyen BN, Amdur RL, Abugideiri M, Rahbar R, Neville RF, Sidawy AN. Postoperative complications after common femoral endarterectomy. J Vasc Surg. 2015 Jun;61(6):1489-94.e1. doi: 10.1016/j.jvs.2015.01.024. Epub 2015 Feb 19.
PubMed 25702917Shammas NW, Abi Doumet A, Karia R, Khalafallah R. An Overview of the Treatment of Symptomatic Common Femoral Artery Lesions with a Focus on Endovascular Therapy. Vasc Health Risk Manag. 2020 Feb 20;16:67-73. doi: 10.2147/VHRM.S242291. eCollection 2020.
PubMed 32110032Bonvini RF, Rastan A, Sixt S, Noory E, Schwarz T, Frank U, Roffi M, Dorsaz PA, Schwarzwalder U, Burgelin K, Macharzina R, Zeller T. Endovascular treatment of common femoral artery disease: medium-term outcomes of 360 consecutive procedures. J Am Coll Cardiol. 2011 Aug 16;58(8):792-8. doi: 10.1016/j.jacc.2011.01.070.
PubMed 21835313Linni K, Ugurluoglu A, Hitzl W, Aspalter M, Holzenbein T. Bioabsorbable stent implantation vs. common femoral artery endarterectomy: early results of a randomized trial. J Endovasc Ther. 2014 Aug;21(4):493-502. doi: 10.1583/14-4699R.1.
PubMed 25101576Stavroulakis K, Schwindt A, Torsello G, Beropoulis E, Stachmann A, Hericks C, Bollenberg L, Bisdas T. Directional Atherectomy With Antirestenotic Therapy vs Drug-Coated Balloon Angioplasty Alone for Common Femoral Artery Atherosclerotic Disease. J Endovasc Ther. 2018 Feb;25(1):92-99. doi: 10.1177/1526602817748319. Epub 2017 Dec 18.
PubMed 29251204Garcia LA, Lyden SP. Atherectomy for infrainguinal peripheral artery disease. J Endovasc Ther. 2009 Apr;16(2 Suppl 2):II105-15. doi: 10.1583/08-2656.1.
PubMed 19624078Brodmann M, Werner M, Brinton TJ, Illindala U, Lansky A, Jaff MR, Holden A. Safety and Performance of Lithoplasty for Treatment of Calcified Peripheral Artery Lesions. J Am Coll Cardiol. 2017 Aug 15;70(7):908-910. doi: 10.1016/j.jacc.2017.06.022. No abstract available.
PubMed 28797363Brodmann M, Werner M, Holden A, Tepe G, Scheinert D, Schwindt A, Wolf F, Jaff M, Lansky A, Zeller T. Primary outcomes and mechanism of action of intravascular lithotripsy in calcified, femoropopliteal lesions: Results of Disrupt PAD II. Catheter Cardiovasc Interv. 2019 Feb 1;93(2):335-342. doi: 10.1002/ccd.27943. Epub 2018 Nov 25.
PubMed 30474206Adams G, Shammas N, Mangalmurti S, Bernardo NL, Miller WE, Soukas PA, Parikh SA, Armstrong EJ, Tepe G, Lansky A, Gray WA. Intravascular Lithotripsy for Treatment of Calcified Lower Extremity Arterial Stenosis: Initial Analysis of the Disrupt PAD III Study. J Endovasc Ther. 2020 Jun;27(3):473-480. doi: 10.1177/1526602820914598. Epub 2020 Apr 3.
PubMed 32242768Adams G, Soukas PA, Mehrle A, Bertolet B, Armstrong EJ. Intravascular Lithotripsy for Treatment of Calcified Infrapopliteal Lesions: Results from the Disrupt PAD III Observational Study. J Endovasc Ther. 2022 Feb;29(1):76-83. doi: 10.1177/15266028211032953. Epub 2021 Aug 12.
PubMed 34380334Baig M, Kwok M, Aldairi A, Imran HM, Khan MS, Moustafa A, Hyder ON, Saad M, Aronow HD, Soukas PA. Endovascular Intravascular Lithotripsy in the Treatment of Calcific Common Femoral Artery Disease: A Case Series With an 18-Month Follow-Up. Cardiovasc Revasc Med. 2022 Oct;43:80-84. doi: 10.1016/j.carrev.2022.05.003. Epub 2022 May 7.
PubMed 35595607Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, Jones DN. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997 Sep;26(3):517-38. doi: 10.1016/s0741-5214(97)70045-4.
PubMed 9308598Tepe G, Brodmann M, Werner M, Bachinsky W, Holden A, Zeller T, Mangalmurti S, Nolte-Ernsting C, Bertolet B, Scheinert D, Gray WA; Disrupt PAD III Investigators. Intravascular Lithotripsy for Peripheral Artery Calcification: 30-Day Outcomes From the Randomized Disrupt PAD III Trial. JACC Cardiovasc Interv. 2021 Jun 28;14(12):1352-1361. doi: 10.1016/j.jcin.2021.04.010.
PubMed 34167675
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Shockwave™ vs Surgical Endarterectomy for Calcified Severe Common Femoral Artery Stenosis: Comparison of Efficacy, Safety and Long-Term Outcomes
- ClinicalTrials.gov ID
- NCT06829914
- Acronym / sponsor ID
- Shockify / 021-263
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Baylor Research InstituteUniversity, hospital or other
- Study start
- 7 Mar 2024 (actual)
- Primary completion
- 3 Nov 2026 (actual)
- Study completion
- 30 Dec 2026 (estimated)
- First posted
- 17 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigators hypothesize that Shockwave with DCB is non-inferior to surgical endarterectomy for common femoral artery (CFA) stenosis with regard to primary efficacy and safety endpoints. The study will challenge the current guideline that recommends common femoral endarterectomy (CFE) as the primary treatment for symptomatic CFA stenosis.
Detailed description
This is a pilot, prospective, randomized clinical trial. This trial compares patients with severe symptomatic moderate to severe calcified CFA stenosis undergoing traditional gold standard CFA endarterectomy to innovative technique of endovascular treatment using Shockwave™ Intra vascular Lithotripsy (IVL) using M5+ balloon with Drug coated balloon to achieve removal and debulking of plaque and achieve luminal gain. Patients who meet inclusion criteria will be informed and consented by a clinical coordinator if they wish to participate in the trial. If participants are candidates for surgery, they will then be randomized into one of two cohorts, receiving either Shockwave™ IVL + DCB (drug-coated balloon) procedure or a standard surgical endarterectomy. The study compares the 1-year efficacy and 6-month safety outcomes post-procedure for patients with severe, symptomatic CFA stenosis receiving Shockwave™ IVL with DCB versus surgical endarterectomy.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Prospective, randomized pilot study
| Arm | Type | Receives |
|---|---|---|
| Shockwave Catheter | Active comparator | Device: Shockwave CatheterShockwave™ Intravenous Lithotripsy (IVL)+ DCB (Drug Coated Balloon) |
| surgical endarterectomy | Active comparator | Procedure: CFA EndarterectomySurgery should be performed with patch angioplasty, with or without profunda femoris endarterectomy. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- A patient will be eligible for inclusion in this study if he or she meets all of the following criteria (confirmed by core lab):
- CFA atherosclerotic stenosis 60-100%
- Moderate to severe calcification reported on imaging
- Lifestyle-limiting intermittent claudication (IC) or chronic limb-threatening ischemia (CLTI) as described by Rutherford chronic limb ischemia (CLI) category 2-5
- Failing conservative therapy
Key exclusion criteria (14 listed)
- A patient will be ineligible for inclusion in this study if he or she meets any of the following criteria:
- History of CFE or bypass in affected limb
- Thrombosis of affected CFA
- Aneurysm in the common femoral artery of target limb
- Known target lesion restenosis (re-narrowing of the artery to ≥50% following the alleviation of a previous narrowing within 3 months)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Shockwave CatheterShockwave™ IVL + DCB procedure | Device | Shockwave Catheter |
| CFA EndarterectomyStandard CFA endarterectomy | Procedure or surgery | surgical endarterectomy |
Primary outcome
Clinically driven target lesion revascularization (cdTLR (symptom-driven repeat revascularization of the index lesion))
Time frame: Procedure date through 1-year post-op
Restenosis to ≥ 50% of the target lesion on angiography or follow-up ultrasound
Time frame: Procedure date through 1-year post-op
Freedom from perioperative death
Time frame: Procedure date through 30 days post-op
Freedom from major adverse cardiovascular events (MACE (stroke, myocardial infarction (MI), cardiovascular death))
Time frame: Procedure date through 30 days post-op
Freedom from major adverse events
Time frame: Procedure date through 6 months post-op
1. Acute occlusion of the target lesion 2. Flow-limiting dissection of the target lesion 3. Symptomatic thrombus or embolus in treated limb requiring treatment 4. Unplanned percutaneous/surgical revascularization or amputation above the ankle of the treated limb 5. Access/surgical site complications 1. Bleeding events (specify Bleeding Academic Research Consortium (BARC) type - see Appendix 18.2) 2. Surgical site infection requiring medication or surgery, wound dehiscence, patch/arterial infection, lymphatic leak requiring surgery
22 secondary outcomes
Mortality
Time frame: Procedure date through 1-year post-op
Rutherford Chronic Limb Ischemia (CLI) Category
Time frame: 30 days post-op, 3 months post-op, 6 months post-op, 1 year post-op
Treatment satisfaction and quality of life (PAQ)
Time frame: Pre-op, 30 days post-op, 6 months post-op, 1 year post-op
Intraoperative blood transfusion > 4 minutes
Time frame: Intra-op
Procedural duration (minutes)
Time frame: Intra-op
Length of stay (days)
Time frame: Procedure date through 1 year post-op
Postoperative anemia requiring blood transfusion
Time frame: Procedure date through 30 days post-op
Readmissions
Time frame: 30 days post-op, 30 days post-discharge
Return to the operating room / angiography suite
Time frame: 30 days post-op
Access/surgical site complications
Time frame: 30 days post-op, 6 months post-op
Pneumonia (number of cases)
Time frame: Procedure date through 30 days post-op
Prolonged intubation
Time frame: Procedure date through 30 days post-op
Urinary tract infection
Time frame: Procedure date through 30 days post-op
Sepsis
Time frame: Procedure date through 30 days post-op
Septic shock
Time frame: Procedure date through 30 days post-op
Graft failure
Time frame: Procedure date through 30 days post-op
Cardiac arrest
Time frame: Procedure date through 30 days post-op
Myocardial infarction
Time frame: Procedure date through 30 days post-op
Acute kidney injury
Time frame: Procedure date through 30 days post-op
Dialysis
Time frame: Procedure date through 30 days post-op
Deep vein thrombosis
Time frame: Procedure date through 30 days post-op
Pulmonary embolism
Time frame: Procedure date through 30 days post-op
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2026.
- Background: PubMed 18639427Kang JL, Patel VI, Conrad MF, Lamuraglia GM, Chung TK, Cambria RP. Common femoral artery occlusive disease: contemporary results following surgical endarterectomy. J Vasc Surg. 2008 Oct;48(4):872-7. doi: 10.1016/j.jvs.2008.05.025. Epub 2008 Jul 17.
- Background: PubMed 26902450Kuma S, Tanaka K, Ohmine T, Morisaki K, Kodama A, Guntani A, Ishida M, Okazaki J, Mii S. Clinical Outcome of Surgical Endarterectomy for Common Femoral Artery Occlusive Disease. Circ J. 2016;80(4):964-9. doi: 10.1253/circj.CJ-15-1177. Epub 2016 Feb 19.
- Background: PubMed 25702917Nguyen BN, Amdur RL, Abugideiri M, Rahbar R, Neville RF, Sidawy AN. Postoperative complications after common femoral endarterectomy. J Vasc Surg. 2015 Jun;61(6):1489-94.e1. doi: 10.1016/j.jvs.2015.01.024. Epub 2015 Feb 19.
- Background: PubMed 32110032Shammas NW, Abi Doumet A, Karia R, Khalafallah R. An Overview of the Treatment of Symptomatic Common Femoral Artery Lesions with a Focus on Endovascular Therapy. Vasc Health Risk Manag. 2020 Feb 20;16:67-73. doi: 10.2147/VHRM.S242291. eCollection 2020.
- Background: PubMed 21835313Bonvini RF, Rastan A, Sixt S, Noory E, Schwarz T, Frank U, Roffi M, Dorsaz PA, Schwarzwalder U, Burgelin K, Macharzina R, Zeller T. Endovascular treatment of common femoral artery disease: medium-term outcomes of 360 consecutive procedures. J Am Coll Cardiol. 2011 Aug 16;58(8):792-8. doi: 10.1016/j.jacc.2011.01.070.
- Background: PubMed 25101576Linni K, Ugurluoglu A, Hitzl W, Aspalter M, Holzenbein T. Bioabsorbable stent implantation vs. common femoral artery endarterectomy: early results of a randomized trial. J Endovasc Ther. 2014 Aug;21(4):493-502. doi: 10.1583/14-4699R.1.
- Background: PubMed 29251204Stavroulakis K, Schwindt A, Torsello G, Beropoulis E, Stachmann A, Hericks C, Bollenberg L, Bisdas T. Directional Atherectomy With Antirestenotic Therapy vs Drug-Coated Balloon Angioplasty Alone for Common Femoral Artery Atherosclerotic Disease. J Endovasc Ther. 2018 Feb;25(1):92-99. doi: 10.1177/1526602817748319. Epub 2017 Dec 18.
- Background: PubMed 19624078Garcia LA, Lyden SP. Atherectomy for infrainguinal peripheral artery disease. J Endovasc Ther. 2009 Apr;16(2 Suppl 2):II105-15. doi: 10.1583/08-2656.1.
- Background: PubMed 28797363Brodmann M, Werner M, Brinton TJ, Illindala U, Lansky A, Jaff MR, Holden A. Safety and Performance of Lithoplasty for Treatment of Calcified Peripheral Artery Lesions. J Am Coll Cardiol. 2017 Aug 15;70(7):908-910. doi: 10.1016/j.jacc.2017.06.022. No abstract available.
- Background: PubMed 30474206Brodmann M, Werner M, Holden A, Tepe G, Scheinert D, Schwindt A, Wolf F, Jaff M, Lansky A, Zeller T. Primary outcomes and mechanism of action of intravascular lithotripsy in calcified, femoropopliteal lesions: Results of Disrupt PAD II. Catheter Cardiovasc Interv. 2019 Feb 1;93(2):335-342. doi: 10.1002/ccd.27943. Epub 2018 Nov 25.
- Background: PubMed 32242768Adams G, Shammas N, Mangalmurti S, Bernardo NL, Miller WE, Soukas PA, Parikh SA, Armstrong EJ, Tepe G, Lansky A, Gray WA. Intravascular Lithotripsy for Treatment of Calcified Lower Extremity Arterial Stenosis: Initial Analysis of the Disrupt PAD III Study. J Endovasc Ther. 2020 Jun;27(3):473-480. doi: 10.1177/1526602820914598. Epub 2020 Apr 3.
- Background: PubMed 34380334Adams G, Soukas PA, Mehrle A, Bertolet B, Armstrong EJ. Intravascular Lithotripsy for Treatment of Calcified Infrapopliteal Lesions: Results from the Disrupt PAD III Observational Study. J Endovasc Ther. 2022 Feb;29(1):76-83. doi: 10.1177/15266028211032953. Epub 2021 Aug 12.
Related trials for Common Femoral Artery Stenosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sameh Sayfo, MD principal investigator
Baylor Scott & White The Heart Hospital - Plano
John Kedora, MD principal investigator
Baylor Scott & White The Heart Hospital - Plano
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Shockwave Catheter and CFA Endarterectomy in people with Common Femoral Artery Stenosis and Calcification; Heart, run by Baylor Research Institute at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Clinically driven target lesion revascularization (cdTLR (symptom-driven repeat revascularization of the index lesion)) (time frame: Procedure date through 1-year post-op). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06829914, which also lists 17 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.